A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
A Phase III, Randomized, Double-blind, Multicenter Study of SHR-8068 and Adebrelimab Plus Bevacizumab in Combination With TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Junqin Yang
- 电话号码:+86-0518-82342973
- 邮箱:junqin.yang@hengrui.com
研究联系人备份
- 姓名:Huan Wang
- 电话号码:+86-0518-82342973
- 邮箱:huan.wang.hw396@hengrui.com
学习地点
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210009
- Zhongda Hospital Southeast University
-
首席研究员:
- Gaojun Teng
-
接触:
- Gaojun Teng
- 电话号码:+86-025-83272084
- 邮箱:gjteng@seu.edu.cn
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- Zhongshan Hospital, Fudan University
-
首席研究员:
- Jia Fan
-
接触:
- Jia Fan
- 电话号码:+86-021-64041990
- 邮箱:fan.jia@zs-hospital.sh.cn
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 18-75 years old, male or female;
- Diagnosis confirmed HCC by pathologically or clinically;
- At least one measurable lesion;
- Child-Pugh liver function grade A;
- ECOG-PS score: 0 or 1;
- Eligible for TACE treatment as assessed by the investigator;
- Participants with HBV or HCV infection must be on and remain on standard antiviral therapy throughout the study period;
- Consent to contraception.
Exclusion Criteria:
- Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma / hepatocellular carcinoma; Participants with other malignancies currently or within the past 5 years;
- Participants with any active, known or suspected autoimmune disorder;
- Participants with hypertension which cannot be well controlled by antihypertensives;
- Uncontrolled cardiac diseases or symptoms;
- Participants with hepatic encephalopathy;
- Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment;
- History of gastrointestinal perforation and/or fistula;
- Participants with other potential factors that may affect the study results.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Treatment group A
SHR-8068 + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE) |
SHR-8068 + Adebrelimab + Bevacizumab, intravenous infusion, Transarterial Chemoembolization (TACE) |
|
有源比较器:Treatment group B
SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo + Transarterial Chemoembolization (TACE) |
SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, intravenous infusion, Transarterial Chemoembolization(TACE) |
|
实验性的:Treatment group C
SHR-8068 Placebo + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE) |
SHR-8068 Placebo + Adebrelimab + Bevacizumab, intravenous infusion, Transarterial Chemoembolization (TACE) |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Progression-free survival (PFS) assessed by investigator
大体时间:Until progression, assessed up to approximately 2 years.
|
Until progression, assessed up to approximately 2 years.
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Adverse events (AEs)
大体时间:Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Serious adverse events (SAEs)
大体时间:Until study completion, assessed up to approximately 3 years.
|
Until study completion, assessed up to approximately 3 years.
|
|
Progression-free survival (PFS) assessed by Blinded Independent Review Committee (BIRC)
大体时间:Until progression, assessed up to approximately 2 years.
|
Until progression, assessed up to approximately 2 years.
|
|
Overall survival (OS)
大体时间:Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Objective response rate (ORR)
大体时间:Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Disease control rate (DCR)
大体时间:Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Duration of objective tumor response (DoR)
大体时间:Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Pharmacokinetics parameters of SHR-8068 and Adebrelimab: serum concentration
大体时间:Approximately 90 days post-last dose.
|
Approximately 90 days post-last dose.
|
|
Immunogenicity indicators of SHR-8068 and Adebrelimab: drug resistant antibody (ADA) and neutralizing antibody (NAb)
大体时间:Approximately 90 days post-last dose.
|
Approximately 90 days post-last dose.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.